DOCSLIB.ORG

ISSN: 2320-5407 Int. J. Adv. Res. 9(06), 816-821

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ISSN: 2320-5407 Int. J. Adv. Res. 9(06), 816-821 ISSN: 2320-5407 Int. J. Adv. Res. 9(06), 816-821 Journal Homepage: - www.journalijar.com Article DOI: 10.21474/IJAR01/13083 DOI URL: http://dx.doi.org/10.21474/IJAR01/13083 RESEARCH ARTICLE WHAT IS CORONAVIRUS, THEIR PREVENTION AND TREATMENTS AND SOME GOVERNMNET POLICIES IN INDIA Babita1, Rajat2, Nivedan Bhardwaj3 and Nivedita3 1. Rnb Global University, Bikaner Rajasthan. 2. Lord Shiva College Of Pharmacy, Sirsa Haryana. 3. Kartar Memorial Collage Of Education. …………………………………………………………………………………………………….... Manuscript Info Abstract ……………………. ……………………………………………………………… Manuscript History The name “coronavirus” comes from the crown- like spike that cowl Received: 25 April 2021 the surfaces of coronaviridae family. The 2019 novel coronavirus is Final Accepted: 28 May 2021 getting plenty ofinterest now due to the factit's milesa brandnewform of Published: June 2021 coronavirus. We have now no longervisibleamongst human before. The idea is that it is able to have jumped from an animal species into the human population, after whichall started spreading. We have visiblea fewhuman beingswhich have died of this ailment, and we recognize that there are already thousands of cases. So human beings are concerned, due to the fact we do now no longerbutrecognizeprecisely how intense the ailmentmay be or how a long wayit's going tounfold. Also, don't forget that coronavirus has an incubation duration of up to fourteen days, and also youought toareseeking forclinicalinterest if the signs persist or get worsepast 7 to ten days. PM Modi recites shloka to stress on collective strength against coronavirus:“Utsaho balavanarya nastyutsahat param balam | Uthsaharambhamatrena jayante sarvasampadah.Meaning there is no force greater than our enthusiasm and spirit in this world. There is nothing in the world that cannot be achieved with this force. Copy Right, IJAR, 2021,. All rights reserved. …………………………………………………………………………………………………….... Introduction:- Coronavirus attainhuman beingsthrutouch with animals. This consists of animals along with the livestock, which includes camels, and others, along with bats and cats. Prime Minister Narendra Modi’s order for the country’s 1.3 billion people to stay home, is an escalation of the 07.00-21.00 “Janata curfew” introduced on march 22, and it comes a day after the government grounded all domestic flights. Mr. Modi reportedly declared that the lockdown applies to “every district, every lane, every village”, and warned that “if you can’t handle these 21 days, this country will go back 21 years. Corona virus are RNA viruses and have crown like appearance when observed under microscope.Four subtypes of corona virus- alpha, beta, gamma, and delta. Corona Virus Classification: Kingdom: Orthornavirae Phylum: Pisuviricota Corresponding Author:- Babita 816 Address:- Rnb Global University, Bikaner Rajasthan. ISSN: 2320-5407 Int. J. Adv. Res. 9(06), 816-821 Class: Pisoniviricetes Order: Nidovirales Family:Coronaviridae Data Of Suffering From Coronavirus Toatl In Haryana: TOTAL CASES: 7.67L RECOVERED: 7.56L DEATH: 9,246 Total In India: TOTAL CAESE: 2.99Cr RECOVERED: 2.88Cr DEATH: 3.88L WORLDWIDE CASE: 17,87,30,551 INDIA: 2,99,35,221 HARYANA: 7,67,418 Common human coronaviruses: These 4 coronaviruses usuallypurposeslightbreathing illness, along with the not unusualplace cold, in human beings. They are: *229E *NL63 *OC43 *HKU1 SARS- CoV: This virus reasonsintense acute breathing syndrome, or SARS. The first instances of this disorder in human beingspassed offwithinside the Guangdong province of china in 2002. In total, SARS unfoldthroughout 26 countries. The signs of SARS include: *a fever *tiredness *chills *muscle aches *a cough *diarrhea In intenseinstances, SARS reasons a loss of oxygen withinside the blood, main to dying in 10% of human beings. MERS-CoV: This syndrome reasons Middle East breathing syndrome, or MERS. The first instancespassed off in Saudi Arabia in 2012. MERS reasons: *a fever *a cough *shortness of breath SARS-CoV-2: is the virus that reasons COVID-19. The first instances of COVID-19 were diagnosedwithinside themetropolis of Wuhan, China, in 2019. Common signs include: *a fever *a cough *chills *tiredness *frame aches 817 ISSN: 2320-5407 Int. J. Adv. Res. 9(06), 816-821 *headache *a sore throat *diarrhea Most not unusualplacesigns: Fever Dry cough Tiredness Less not unusualplacesigns: Aches &ache Sore throat Diarrhea Headache Loss of flavor or smells. How COVID 19 spreads: Close touch (6 feet) Respiratory droplets, cough, sneeze, or talks. Touching floor or item that has the virus on it, then touching mouth, nostril, or eyes. Severe acute breathing syndrome Coronavirus 2 (SARS-CoV-2): It is a brand newstress that reasons the COVID-19 disorder. Most Affected Organ By Corona: Lungs are maximumlaid low with coronavirus due to the fact the virus accesses host cells through the receptor for the enzyme angiotensin- changing enzyme 2 (ACE2), that'smaximumplentifulat thefloor of kind II alveolar cells of the lungs. MASK: can assist for save you the unfold of virus. Mask by myself do now no longerguardtowards COVID-19, &ought to be blended with distancing and hand hygiene. Vaccines: 1)COVAXIN VACCINES 2)COVISHIELD VACCINES 3)SPUTNIK V VACCINES 1)COVAXINE VACCINES: is a vaccine that objectives to guard peoples towards COVID-19. Manufacture via way of means of: Bharat Biotech Research name: BBV152 Vaccine kind: Inactivated Administration method: intramuscular injection 2)COVISHIELD VACCINES: is a vaccine that objectives to guard peoples towards COVID-19. Manufacture via way of means of: Astrazeneca, serum institute of India. Research name: AZD1222(ChAdOx1) Vaccine kind: Non-Replicating Viral vector Administration method: intramuscular injection 3)SPUTNIK VACCINES: is a vaccine that objectives to guard peoples towards COVID-19. Manufacture via way of means of: Gamaleya Research institute Research name: Gram COVID Vaccine Vaccine kind: Non-replicating viral vector Administration method: Intramuscular injection List of covid vaccine made in India: vaccine status approval deployment covishield In use 1 january2021 16 january2021 covaxin In use 3 january2021 16 january2021 Sputnik V Approved for use 12april2021 14 may 2021 818 ISSN: 2320-5407 Int. J. Adv. Res. 9(06), 816-821 List of vaccine under trial in india vaccine Technology Phase 1 Phase 2 ZyCoV-D DNA (plasmid expressing completed completed SARS-CoV-2 S protein) Bio E Subunit (using an antigen) completed completed COVID-19 HGC019 RNA In progress - BBV154 Adenovirus vector In progress - (intranasal) Covovax SARA-CoV-2 completed completed recombinant spike protein nanoparticle vaccine (SARS-CoV-2rS) with Matrix-M1 tm adjuvantS Register for vaccination: Co- WIN Portal &agenda your vaccination appointment. http://www.cowin.gov.in/domestic. Strains of COVID: Strain disease discovered SARS- CoV or SARS-CoV-1 Severe acute respiratory syndrome 2003 (SARS) Human Coronavirus NL63 (HCoV- Severe bronchiolitis Late 2004 NL63) Human coronavirus HKU1(HCoV- Sever URTI 2005 HKU1) Middle East respiratory syndrome- Middle East respiratory syndrome 2012 related coronavirus (MERS-CoV), (MERS) or EMC/2012(HCoV-EMC/2012) SARS-CoV-2 COVID-19 2019 Who ought tonow no longer take vaccine Every day, many peoples are demisebecause of coronavirus, you get your vaccination as quickly as possible. About a hundred million human beings in India have were given the vaccine. During waves of coronavirus, many human beings have died and now 0.33 wave of COVID-19 may also come, which may be very dangerous. Doctors informed that if any individual getting the vaccine, the threat of coronavirus are decreased and dose of vaccine need to be taken, at distinct times. Who ought tonow no longer take corona vaccine: * Pregnant girlscan’t take this vaccine. *This vaccine is secure for the oneswho've asthma, liver issues or kidney sicknesses etc. * People who're allergic to foods, insects, environmental triggers, animal etc., can without problems get their vaccine. * Those whose platelets are very low ought to take this vaccine with amazing caution. *Women also can get the Covid-19 vaccine of theirduration cycle. Prevention Guardyourself& others round you via way of means ofunderstanding the facts &taking appropriate precautions. To save you the unfold of coronavirus (COVID-19): *Proper smooth your arms, use soap & water. *Maintain a way from absolutely everyonewho'slaid low with cough, sneezing etc. *Wear a maskwhilst distance isn't possible. *Do now no longercontact your eyes, nostril or mouth. *Stay domesticin case youexperiencenow no longer good. *If you've got cold &problem in breathing, are seeking forclinicalinterest. *Wash arms regularly 819 ISSN: 2320-5407 Int. J. Adv. Res. 9(06), 816-821 * Use an alcohol-primarily based totally sanitizer *Keep your environmentsmooth *Cover your nostril and mouth whilst sneezing and coughing. *Discard used tissue. * Avoid eatinguncooked meat and milk without boiling it nicely General recommendations to holdyourselfsecure from the coronavirus: If touring overseas, make sure you improve your immunity and bringcriticalmedicinal drugs for fever, cough and cold. How is the coronavirus diagnosed: lab tests, which includesnostril and throat lifestyle and blood paintings can diagnose whether or not your signs are as a result of coronavirus. How lengthy does the coronavirus live: It is difficult to are expecting how lengthy the coronavirus outbreak will last, specially, on the grounds thatnow no longertonsis thoughtapproximately the lateststress affecting peoples. Treatment Self-care:
Load more

Recommended publications
  • What Do We Know About India's Covaxin Vaccine?
    FEATURE Tamil Nadu, India COVID-19 VACCINES [email protected] BMJ: first published as 10.1136/bmj.n997 on 20 April 2021. Downloaded from Cite this as: BMJ 2021;373:n997 http://dx.doi.org/10.1136/bmj.n997 What do we know about India’s Covaxin vaccine? Published: 20 April 2021 India has rapidly approved and rolled out Covaxin, its own covid-19 vaccine. Kamala Thiagarajan examines what we know so far. Kamala Thiagarajan freelance journalist Who developed Covaxin? cheapest purchased by any country in the world at 206 rupees per shot for the 5.5 million doses the Covaxin was developed by Indian pharmaceutical government currently has on order. The government company Bharat Biotech in collaboration with the has capped the price of the vaccine sold in the private Indian Council of Medical Research, a government market, with private hospitals able to charge up to funded biomedical research institute, and its 250 rupees.13 subsidiary the National Institute of Virology. Covaxin does not require storage at sub-zero Bharat Biotech has brought to market 16 original temperatures, which would be hard to maintain in vaccines, including for rotavirus, hepatitis B, Zika India’s climate and with the frequent power cuts in virus, and chikungunya.1 The company reportedly rural areas. Covaxin is available in multi-dose vials spent $60-$70m (£43-£50m; €50-€58m) developing and is stable at the 2-8°C that ordinary refrigeration Covaxin.2 can achieve. How does Covaxin work? Bharat Biotech says it has a stockpile of 20 million The vaccine is similar to CoronaVac (the Chinese doses of Covaxin for India and is in the process of vaccine developed by Sinovac)3 in that it uses a manufacturing 700 million doses at its four facilities complete infective SARS-CoV-2 viral particle in two cities by the end of the year.
    [Show full text]
  • Vaccination What Is Vaccination?
    VACCINATION WHAT IS VACCINATION? Vaccination is a simple, safe, and effective way of protecting people against harmful diseases, before they come into contact with them. Makes your immune system stronger. Vaccines train your immune system to create antibodies. SOURCE : World Health Organization Why You Should Get Vaccinated? COVID-19 vaccines are safe and effective. When we get vaccinated, we aren’t just protecting ourselves, but also those around us. Helps to reduce the spread of disease. SOURCE : World Health Organizations Are Vaccines Safe? Vaccination is safe. The benefits of vaccination greatly outweigh the risks, and many more illnesses and deaths would occur without vaccines. SOURCE : World Health Organization Side Effects Of Vaccines Like any medicine, vaccines can cause mild side effects, such as a low- grade fever, or pain or redness at the injection site. Severe or long-lasting side effects are extremely rare. Vaccines are continually monitored for safety, to detect rare adverse events. SOURCE : World Health Organization Types Of Vaccines In India 1. Covaxin 2. Covishield 3. ZyCoV-D 4. Sputnik 5. BBV154 – Intranasal Vaccine 6. Moderna 7. Pfizer SOURCE : Indian Council Of Medical Research Details About Covaxin Covaxin is an inactivated vaccine which means that it is made up of killed coronaviruses, making it safe to be injected into the body. When administered, immune cells can still recognise the dead virus, prompting the immune system to make antibodies against the pandemic virus. The two doses are given four weeks apart. The vaccine can be stored at 2C to 8C. SOURCE : BBC Details About Covishield The vaccine is made from a weakened version of a common cold virus (known as an adenovirus) from chimpanzees.
    [Show full text]
  • 0 January to July 2021
    0 www.journalsofindia.com January to July 2021 SCIENCE & TECH ............................................................................................................................................................... 6 1. REUSABLE LAUNCH VEHICLE TECHNOLOGY DEMONSTRATION PROGRAMME(RLV-TD) ................................................. 6 2. GAGANYAAN MISSION ..................................................................................................................................................... 6 3. MARS ORBITER MISSION (MOM) ..................................................................................................................................... 6 4. CHANDRAYAAN MISSION................................................................................................................................................. 7 5. SOLAR MISSION ............................................................................................................................................................... 8 6. ARTEMIS ACCORD ............................................................................................................................................................ 9 7. NATIONAL MISSION ON INTERDISCIPLINARY CYBER-PHYSICAL SYSTEM (NMICPS) ....................................................... 10 8. SMART ANTI-AIRFIELD WEAPON (SAAW) ...................................................................................................................... 10 9. AQUAPONICS ................................................................................................................................................................
    [Show full text]
  • Bcpct]Ttsbc^Prc U^A Dq[XRV^^S
    6 < %()(=#%% 53%7==,>3='$()6(=#%% (#-'>3='$()6(=#%% $'()"*$+&,- %( !"# $$%& 2(*3-% (566)(37)% 3 0 4 $5 3 $1 2 0 .8 9 8 ++0 0 .:; . !" . / 01 $ %'( $) '# *' it for the last eight to nine notable achievements to its months, “where is the UN in name in the 75 years of its aking a strong case for a this joint fight. Where is the experience, including the pre- Msignificant role for India effective response.” vention of a third world war, in the United Nations, Prime Focussing on a more “we can’t deny terrorist attacks 0 Minister Narendra Modi on prominent role for India in the shook the world”. Saturday stressed the need for UN and fight against corona, “We have successfully ne of the oldest partners changes in the international the Prime Minister avoided avoided a third world war but Oof the BJP — the body and questioned its posi- making any reference to ongo- we cannot deny many wars Shiromani Akali Dal — which tion in fighting the coron- ing tension at the Line of happened, many civil wars has been with it through thick avirus pandemic. Actual Control (LAC) and happened. Terrorist attack and thin for decades, finally He also assured the global frosty ties with Pakistan in his shook the world. Blood was quit the National Democratic Q community that India will pro- 20-minute speech. He also did spilled. Those were killed were Alliance (NDA) on Saturday, vide corona vaccine to the not respond to Pakistan Prime like you and me. Children left signaling a complete political world as it is the world’s biggest Minister Imran Khan’s remarks the world prematurely,” he said.
    [Show full text]
  • COVID-19 Vaccines Update Supplement Week Of: 5Th April, 2021
    CARPHA UPDATE FOR Incident Manager / SITUATION REPORT COVID-19 Vaccines Update Supplement Week of: 5th April, 2021 I. Overview of Development and Regulatory Approvals: • 85 candidate vaccines are in clinical development: 16 in Phase 3 trials, and 4 in Phase 4 trials – see Figure in CARPHA COVID-19 Vaccine Regulatory Tracker (Phases tab). • 13 vaccines have received regulatory approvals in various countries, and 16 vaccines are at various stages of engagement with WHO for emergency use listing (EUL). • 4 vaccines have been approved by WHO for Emergency Use Listing: Pfizer-BioNTech’s vaccine: COMIRNATY®, AstraZeneca-SK Bio, AstraZeneca-SII (Covishield), and Janssen-Cilag. • 4 additional vaccines are expected to be approved by WHO in April – Tables 1 and 3. • There are 3 additional vaccines being considered by WHO but these are at the stage of submitting expressions of interest: Bharat Biotech, Clover Biopharmaceuticals-GSK + Dynavax, and BioCubaFarma (Cuba). • The WHO Strategic Advisory Group of Experts on Immunization (SAGE) interim recommendations and background documents are available for vaccines by: Moderna, Pfizer-BioNTech, AstraZeneca-Oxford and Janssen-Cilag at SAGE Interim Guidance. The recommendations provide guidance on the use the vaccines, including use in various groups. • Reports of rare clotting events among vaccinees continue to be assessed by various regulators. The EU's European Medicines Agency (EMA) has stated that there was no evidence to support decisions by regulators to restrict the use of Oxford-AstraZeneca vaccines in some age groups. The WHO maintains that the benefit-risk balance of the vaccine remains favorable. • CARPHA has shared its COVID-19 vaccine regulatory tracker with Member States for viewing as updates are made.
    [Show full text]
  • V.3 1/25/2021 COVID-19 Vaccine FAQ Sheet
    COVID-19 Vaccine FAQ Sheet (updated 1/25/2021) The AST has received queries from transplant professionals and the community regarding the COVID-19 vaccine. The following FAQ was developed to relay information on the current state of knowledge. This document is subject to change and will be updated frequently as new information or data becomes available. What kinds of vaccines are available or under development to prevent COVID-19? There are currently several vaccine candidates in use or under development. In the United States, the Government is supporting six separate vaccine candidates. Several other vaccines are also undergoing development outside of the United States government sponsorship and further information can be found here: • NYTimes Coronavirus Vaccine Tracker: https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine- tracker.html • Washington Post Vaccine Tracker: https://www.washingtonpost.com/graphics/2020/health/covid-vaccine-update- coronavirus/ The types of vaccines are as follows (January 25, 2021) 1: Table 1: Vaccines Under Development Vaccine Type Compound Name Clinical Trial Notes [Sponsor] Phase mRNA mRNA-1273 Phase 3 Emergency use in [Moderna] U.S., E.U., other countries Approved in Canada BNT162b2 [Pfizer] Phase 2/3 Emergency use in U.S., E.U., other countries Also approved in Canada and other countries Replication- AZD1222 Phase 2/3 Emergency use in defective [AstraZeneca] Britain, India, other adenoviral vector countries (not U.S.) Ad26.COV2.S Phase 3 [Janssen] v.3 1/25/2021 Recombinant- NVX-CoV2373 Phase 3 subunit-adjuvanted [Novavax] protein Recombinant SARS- Phase 1/2 CoV-2 Protein Antigen + AS03 Adjuvant [Sanofi Pasteur/GSK] Inactivated CoVaxin [Bharat Phase 3 Emergency Use in coronavirus Biotech] India BBIBP-CorV Phase 3 Approved China, [Sinopharm] Bahrain, UAE; Emergency use elsewhere (not U.S.) Both of the mRNA SARS-CoV-2 vaccines (Moderna, Pfizer) have been approved by Emergency Use Authorization by the U.S.
    [Show full text]
  • COVID-19 Vaccination Programme: Information for Healthcare Practitioners
    COVID-19 vaccination programme Information for healthcare practitioners Republished 6 August 2021 Version 3.10 1 COVID-19 vaccination programme: Information for healthcare practitioners Document information This document was originally published provisionally, ahead of authorisation of any COVID-19 vaccine in the UK, to provide information to those involved in the COVID-19 national vaccination programme before it began in December 2020. Following authorisation for temporary supply by the UK Department of Health and Social Care and the Medicines and Healthcare products Regulatory Agency being given to the COVID-19 Vaccine Pfizer BioNTech on 2 December 2020, the COVID-19 Vaccine AstraZeneca on 30 December 2020 and the COVID-19 Vaccine Moderna on 8 January 2021, this document has been updated to provide specific information about the storage and preparation of these vaccines. Information about any other COVID-19 vaccines which are given regulatory approval will be added when this occurs. The information in this document was correct at time of publication. As COVID-19 is an evolving disease, much is still being learned about both the disease and the vaccines which have been developed to prevent it. For this reason, some information may change. Updates will be made to this document as new information becomes available. Please use the online version to ensure you are accessing the latest version. 2 COVID-19 vaccination programme: Information for healthcare practitioners Document revision information Version Details Date number 1.0 Document created 27 November 2020 2.0 Vaccine specific information about the COVID-19 mRNA 4 Vaccine BNT162b2 (Pfizer BioNTech) added December 2020 2.1 1.
    [Show full text]
  • Bharat Biotech Inks Licensing Deal with Washington University School of Medicine in St
    Bharat Biotech Inks Licensing Deal with Washington University School of Medicine in St. Louis to advance COVID-19 Intranasal Vaccine Technology Hyderabad, India, 23 September 2020: Vaccine Innovator, Bharat Biotech announces today, a licensing agreement with Washington University School of Medicine in St. Louis for a novel chimp- adenovirus, single dose intranasal vaccine for COVID-19. Bharat Biotech owns the rights to distribute the vaccine in all markets except USA, Japan and Europe. While the Phase I trials will take place in Saint Louis University’s Vaccine & Treatment Evaluation Unit, Bharat Biotech, upon obtaining the required regulatory approval, will pursue further stages of clinical trials in India and undertake large scale manufacture of the vaccine at its GMP facility located in Genome Valley, Hyderabad. We are proud to collaborate on this innovative vaccine. We envision that we will scale this vaccine to 1 billion doses, translating to 1 billion individuals vaccinated receiving a single-dose regimen. An intranasal vaccine will not only be simple to administer but reduce the use of medical consumables such as needles, syringes, etc., significantly impacting the overall cost of a vaccination drive. Our experience in viral vaccines, manufacturing capabilities, and distribution continue to be our strong suit in ensuring safe, efficacious, and affordable vaccines. It is prudent for Bharat to be involved in diverse but tenable projects to provide a much-needed vaccine against COVID-19 reaches all citizens of the world.” Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech, stated. This intranasal vaccine candidate has shown unprecedented levels of protection in mice studies; the technology and data having been recently published in the prestigious scientific journal Cell and in an editorial in Nature.
    [Show full text]
  • Editorial 10.5005/Ijmb-24-3-Iv
    Editorial 10.5005/ijmb-24-3-iv COVID-19 Vaccines: Lets Go for It SARS CoV-2, also christened as COVID-19 is an acute respiratory illness caused by a novel coronavirus which originated from Wuhan China in 2019 and within a short span affected virtually each and every country around the globe, throwing healthcare preparedness and economy out of gear. The world was faced with a pandemic leading to overcrowded hospitals and overflowing mortuaries. Lockdowns imposed in countries jeopardized routine life never to normalize again. India has been among the top three countries with the maximum number of afflicted people. Thankfully , our statistics with respect to mortality is better as compared to the western world. The last year 2020 was completely COVIDISED if we may say so. The world economy is in doldrums and the health infrastructure is overstretched and fatigued. Everytime we feel that the disease is under control, the virus cleverly mutates to become more infective and develops increased ability to escape the immune surveillance. Efforts to develop a vaccine against this scourge were initiated at a war footing across the globe. A number of vaccines were approved for emergency use since the scientific committee didn’t have the time to wait further. In India, two vaccines- Covaxin and Covishield have been approved by the Government of India for mass vaccination. The mammoth program was initiated with first preference for the healthcare workers and frontline warriors. In the next phases, elderly population followed by the rest of the population in a phased manner was planned. It is really incredible and praiseworthy about the immaculate planning and implementation of the initiative in our country where the diversity is both a boon as well as bane.
    [Show full text]
  • Bjpworker Shot PM Modi Chairs CCS Meeting to Dead by Militants in Cases, One Death Review Situation in Afghanistan JAMMU RISING Gus) in the Union Territory
    JAMMU, WEDNESDAY, AUGUST 18, 2021 JAMMU RISING NEWS P-3 NEWS P-5 NEWS P-12 NATIONAL P-8 SPORT P-7 Advisor 9 Doda youth 36 Keralites T20 World Cup: Bhatnagar get Ramban Admin felicitates DPO stranded in Kabul conducts commercial ICC releases with ‘EX- seek urgent help to vehicles schedule, India- extensive CELLENT return home; CM tour of under Pakistan match CIVILSER- reaches out to Jammu MUMKIN VICES AWARD’ on October 24 city scheme Centre Price: Rs.1 | Page 12 | Vol. No.: 11 | Issue No: 191 Postal Registration No. JK-458/16-18 epaper.dailyjammurising.in RNI No: JKENG/2011/40494 BRIEF NEWS J&K reports 83 COVID-19 BJPworker shot PM Modi chairs CCS meeting to dead by militants in cases, one death review situation in Afghanistan JAMMU RISING gus) in the union territory. The Bulletin also informs J&K’s Kulgam JAMMU, AUG 17 The Government on Tues- that no new confirmed case ABJP worker was shot dead NEW DELHI,AUG 17 tional status of Kabul airport. Jammu and Kashmir day informed that 83 new of Mucormycosis has been by militants in Brazloo area of Prime Minister Narendra This has been discussed at recorded 83 fresh COVID- positive cases of novel reported today, thus the total South Kashmir’s Kulgam dis- Modi chaired a meeting of high levels with our partners, 19 cases and one fatality on Corona virus (COVID-19), number of confirmed cases trict today. the Cabinet Committee on including by EAM with the Tuesday, pushing the union 38 from Jammu division and remains 42 in the UT of Militants fired upon BJP In- Security on Tuesday to re- US Secretary of State.
    [Show full text]
  • Article Download (79)
    wjpls, 2020, Vol. 6, Issue 6, 152-161 Review Article ISSN 2454-2229 Pratik et al. World Journal of Pharmaceutical World Journaland Life of Pharmaceutica Sciencesl and Life Science WJPLS www.wjpls.org SJIF Impact Factor: 6.129 THE NOVEL CORONAVIRUS (COVID-19) CAUSATIVE AGENT FOR HUMAN RESPIRATORY DISEASES Pratik V. Malvade1*, Rutik V. Malvade2, Shubham P. Varpe3 and Prathamesh B. Kadu3 1Pravara Rural College of Pharmacy, Pravaranagar, 413736, Dist. - Ahmednagar (M.S.) India. 2Pravara Rural Engineering College, Loni, 413736, Dist. - Ahmednagar (M.S.) India. 3Ashvin College Of Pharmacy, Manchi Hill, Ashvi Bk., 413714, Dist.- Ahmednagar (M.S.) India. *Corresponding Author: Pratik V. Malvade Pravara Rural College of Pharmacy, Pravaranagar, 413736, Dist. - Ahmednagar (M.S.) India. Article Received on 08/04/2020 Article Revised on 29/04/2020 Article Accepted on 19/05/2020 ABSTRACT The newly founded human coronavirus has named as Covid-19. The full form of Covid-19 is “Co-Corona, vi- virus and d- disease”. The Covid-19 is also named as 2019-nCoV because of it was firstly identified at the end of 2019. The coronavirus are the group of various types of viruses i.e. some have positive-sense, single stranded RNA and they are covered within the envelope made up of protein. Still now days seven human coronaviruses are identified are Nl 63, 229E, OC43, HKU1, SARS-CoV, MERS-CoV and latest Covid-19 also known as SARS-CoV-2. From above all, the SARS-CoV and MERS-CoV causes the highest outbreak but the outbreak of Covid-19 is much more than the other any virus.
    [Show full text]
  • Edical Sciences Esearch (IJAMSCR)
    Dr. N. Sriram et al / Int. J. of Allied Med. Sci. and C lin. Research Vol-9(1) 2021 [ 1-10] International Journal of Allied Medical Sciences and Clinical Research (IJAMSCR) ISSN: 2347 -6567 IJAMSCR |Volume 9 | Issue 1 | Jan - Mar - 2021 www.ijamscr.com Review article Medical research Development of new covid -19 vaccines from india : A systematic review 1Dr. N. Sriram, 2S. Kameshwaran , 3Asokkumar DS , 4N. Elavarasan, 5M. Sarbudeen 1Department of Pharmaceutics, Hits College of Pharmacy, Bogaram, Ghatkesar, Hyderabad, Telangana, India 2-5 Excel college of Pharmacy, Komarapalayam, Namakkal, Tamilnadu – 637303. *Corresponding Author :Dr. N. Sriram email: [email protected] ABSTRACT Extreme acute respiratory syndrome Coronavirus 2 (SARS -CoV-2) is an extremely pathogenic new virus that has triggered the current worldwide coronavirus disease pandemic (COVID -19). Currently, substantial effort has been made to produce successful and safe medicines and SARS-CoV-2 vaccines. To avoid more morbidity and death, a successful vaccine is important. Though some regions which deploy COVID -19 vaccines on the basis of protection and immunogenicity data alone, the aim of vaccine research is to obtain d irect proof of vaccine effectiveness in protecting humans against SARS-CoV -2 and COVID-19 infections in order to selectively increase the production of effective vaccines. A SARS-CoV-2 candidate vaccine can function against infection, illness, or transmiss ion and a vaccine that is capable of minimising all of these components may lead to disease control. In this study, we discussed the Bharat Biotech and Covishield Serum Institute of India's Covaxin - India's First Indigenous Covid -19 Vaccine.
    [Show full text]